{
    "nct_id": "NCT03434379",
    "official_title": "A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma",
    "inclusion_criteria": "* Locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC)\n* No prior systemic therapy for HCC. Previous use of herbal therapies/traditional Chinese medicines with anti-cancer activity included in the label is allowed, provided that these medications are discontinued prior to randomization.\n* At least one measurable untreated lesion\n* ECOG Performance Status of 0 or 1\n* Adequate hematologic and end-organ function\n* For women of childbearing potential: agreement to remain abstinent\n* For men: agreement to remain abstinent\n* Child-Pugh class A\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of leptomeningeal disease\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan\n* Known active tuberculosis\n* History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 1 month after the last dose of sorafenib\n* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC\n* Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding\n* A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment.\n* Moderate or severe ascites\n* History of hepatic encephalopathy\n* Co-infection of HBV and HCV\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Uncontrolled or symptomatic hypercalcemia\n* Treatment with systemic immunostimulatory agents\n* Inadequately controlled arterial hypertension\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* Evidence of bleeding diathesis or significant coagulopathy\n* History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration\n* Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture\n* Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses\n* Local therapy to liver within 28 days prior to initiation of study treatment or non-recovery from side effects of any such procedure\n* Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID)",
    "miscellaneous_criteria": ""
}